← Eichor
Condition: Sintilimab Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Sintilimab

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

HAIC Combined With Lenvatinib and PD-1 Inhibitor in Infiltrative Hepatocellular Carcinoma
Phase N/A · 1 location(s) · Sun Yat-sen University · NCT06333561Neoadjuvant Immunochemotherapy in Locally Advanced Esophagogastric Junction Adenocarcinoma
Phase 2 · 1 location(s) · Sun Yat-sen University · NCT05170503Node-sparing Radiotherapy Combined With Total Neoadjuvant CAPOX and Sintilimab for MSS Middle and Low Rectal Cancer
Phase 2 · 1 location(s) · Jinhua Central Hospital · NCT06204094A Study of Sintilimab Combined With Chemotherapy for Neoadjuvant Treatment of Esophageal Squamous Cell Carcinoma
Phase 2 · 1 location(s) · Fujian Cancer Hospital · NCT06463834Locoregional Therapy Combined With Bevacizumab and PD1/L1 Inhibitor in Advanced Hepatocellular Carcinoma
Phase N/A · 1 location(s) · Sun Yat-sen University · NCT06323382Cryoablation Combined with Sintilimab Plus Lenvatinib in Previously Treated Unresectable Liver Metastasis from Solid Tum
Phase 2 · 1 location(s) · Fudan University · NCT05098847Sintilimab Plus Rituximab Followed by R-CHOP Regimen in Untreated PMBL
Phase 2 · 2 location(s) · Sun Yat-sen University · NCT06742502Neoadjuvant Chemotherapy Combined With Sintilimab and Bevacizumab for TNBC (NEOTORCH-BREAST07)
Phase 2 · 2 location(s) · First Affiliated Hospital of Zhejiang University · NCT07351487Bevacizumab in Combination With Sintilimab Versus Transcatheter Arterial Chemoembolization for the Treatment of Intermed
Phase 2 · 1 location(s) · Sun Yat-sen University · NCT06090656The Efficacy and Safety of the Combination of PD-1 With Chemotherapy and Adaptive Radiotherapy Strategy in the Treatment
Phase 2 · 1 location(s) · The Third Xiangya Hospital of Central South University · NCT07138755First Line Sintilimab Combined With Anlotinib and Platinum Doublet Chemotherapy in Malignant Pleural Mesothelioma
Phase 2 · 2 location(s) · Cancer Institute and Hospital, Chinese Academy of Medical Sc · NCT05188859Phase II Trial: Low-Dose Radiation + SBRT + Sintilimab + Chemotherapy vs. Sintilimab + Chemotherapy in Locally Advanced
Phase 2 · 6 location(s) · Sichuan University · NCT06121505Study of ZG005 Combined With Bevacizumab Versus Sintilimab Combined With Bevacizumab in Advanced Hepatocellular Carcinom
Phase 2 · 1 location(s) · Suzhou Zelgen Biopharmaceuticals Co.,Ltd · NCT06558227Adaptive Adjuvant Sintilimab Therapy Guided by MRD (ADAPT Lung)
Phase 2 · 2 location(s) · Guangdong Association of Clinical Trials · NCT07120698Sintilimab Plus Chemotherapy as Neoadjuvant and Adjuvant Treatment for Locally Advanced Oral Squamous Cell Carcinoma
Phase 3 · 1 location(s) · Qunxing Li,MD · NCT07371611A Prospective, Single-arm, Phase II Clinical Trial to Evaluate the Efficacy and Safety of Tafolecimab and Sintilimab Com
Phase 2 · 1 location(s) · Jinghui Wang · NCT06421298Triple Therapy Sequential Radiotherapy in Unresectable HCC (TALENP003)
Phase N/A · 4 location(s) · Fujian Provincial Hospital · NCT06561399Sintilimab, Pegaspargase Plus GemOx for Untreated Extranodal NK/T-Cell Lymphoma
Phase 2 · 1 location(s) · Peking Union Medical College Hospital · NCT06824883BC001 in Combination with Sintilimab and XELOX in the Treatment of HER-2 Negative Advanced or Metastatic Gastric Cancer
Phase 1 · 1 location(s) · Sichuan Luzhou Buchang Biopharmaceutical Co., Ltd. · NCT06773312Study of Fruquintinib Plus Sintilimab for Treatment of Advanced Endometrial Cancer
Phase 3 · 17 location(s) · Hutchmed · NCT06584032PACE: PD-1 Antibody For dMMR/MSI-H Stage III Colorectal Cancer
Phase 3 · 1 location(s) · Sun Yat-sen University · NCT05236972Sintilimab Combined With Tafolecimab and Chemotherapy as First-Line Treatment for Extensive-Stage Small Cell Lung Cancer
Phase 2 · 5 location(s) · Second Affiliated Hospital, School of Medicine, Zhejiang Uni · NCT07061535Nimotuzumab Combined With Sintilimab and Chemotherapy for Advanced Esophageal Squamous Cell Carcinoma
Phase 2 · 1 location(s) · The First Affiliated Hospital of Zhengzhou University · NCT06718205Comparing Modified XELOX Plus Sintilimab With Standard XELOX Plus Sintilimab in First-line Treatment for HER2-negative G
Phase 3 · 10 location(s) · Sun Yat-sen University · NCT05918094Sintilimab Combined With IBI310 and Surufatinib for the Treatment of G3-NET and NEC (NESSIE)
Phase 2 · 2 location(s) · Peking University · NCT05165407Comparing Chidamide+Sintilimab+Bev With Standard Second-line FOLFIRI+Bev in Advanced MSS/pMMR mCRC
Phase 3 · 12 location(s) · Sun Yat-sen University · NCT05768503Adjuvant Radiotherapy of Sintilimab Versus TACE for HCC
Phase 3 · 1 location(s) · Cancer Institute and Hospital, Chinese Academy of Medical Sc · NCT07186621First-line Treatment With RC48 Plus Sintilimab and S-1 in Advanced Gastric Cancer (RCTS2)
Phase 2 · 20 location(s) · Qilu Hospital of Shandong University · NCT06730373Relmacabtagene Autoleucel Combined With Sintilimab for Relapsed/Refractory B-cell Lymphoma
Phase 2 · 3 location(s) · Sun Yat-sen University · NCT07077512A Phase II Clinical Study of Sintilimab Combined with Chemotherapy Followed by Concurrent Chemoradiotherapy for Locally
Phase 2 · 1 location(s) · Shanghai Chest Hospital · NCT06709417
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.